Amazon.com Inc vs Cassava Sciences Inc — how do they compare? Amazon.com Inc trades at $267.2 (market cap $2.94T), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Amazon.com Inc is far larger — about 61570.7× Cassava Sciences Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | FLNA | |
|---|---|---|
Market Cap | $2.94T | $47.75M |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $4.64 |
52-Week Low | $198.79 | $0.87 |
Enterprise Value | $3.04T | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $268.92, down 3.3% over the past 24 hours, but maintains strong fundamental momentum with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion. The stock shows a bullish technical setup with moving averages supporting upward momentum, while analyst sentiment remains overwhelmingly positive with 89% buy ratings and a $333.86 consensus price target representing 24% upside potential.
Amazon's outlook remains favorable with accelerating AI-driven growth in AWS and expanding profit margins, though investors face risks from intense retail competition and substantial capital expenditures. The company's dominant market position and strong cash flow generation support continued expansion, but execution on massive infrastructure investments will be critical for sustained shareholder returns.
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →